Data about possible KRAS mutations in CEC of IPMN patients are still lacking, while a high prevalence of KRAS mutations in IPMN tissue has already been demonstrated. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.